Modulating pyrimidine ribonucleotide levels for the treatment of cancer
The goal in that case is not necessarily to stop berberine but to reduce risk through dose structure and monitoring
"Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo"
Tranexamic Acid targets stubborn pigmentation for a brighter, more uniform complexion
Come in and talk to us
Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)